Plasma Tech claims patent for its product will shake up plasma biopharma market
Privately-held US firm Plasma Technologies announced the recent issuance of US patent No 8,293,242, an "Ultra-High Yield of Alpha-1 Antitrypsin" and the company's plans to commercialize its patented extraction process for plasma biologics.
The company's technology fundamentally changes the economics of blood plasma fractionation by substantially increasing the yield of alpha-1 antitrypsin (AAT) and intravenous immune globulin (IVIG) and makes possible the extraction of several additional therapeutically useful plasma proteins. The non-denaturing process will enable plasma-derived biologics to be differentiated on the basis of improved molecular integrity that will enhance patient tolerance, will minimize the danger of thromboembolic events and will preserve the serum half-lives of the biomolecules.
Current $15 billion global market substantially underserved
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze